Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting) QNTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.89
- Day Range
- $3.84–4.25
- 52-Week Range
- $2.07–38.25
- Bid/Ask
- $3.94 / $4.00
- Shares Outstanding
- 6.40M
- Market Cap
- $25.15M
- Volume/Avg
- 187,492 / 550,481
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.quantumbiopharma.com
Valuation
|
Metric
|
QNTM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 38.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
QNTM
Financial Strength
|
Metric
|
QNTM
|
|---|---|
Quick Ratio | 0.29 |
Current Ratio | 0.63 |
Interest Coverage | −101.61 |
Quick Ratio
QNTM
Profitability
|
Metric
|
QNTM
|
|---|---|
Return on Assets (Normalized) | −50.97% |
Return on Equity (Normalized) | −161.51% |
Return on Invested Capital (Normalized) | −132.14% |
Return on Assets
QNTM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ygjzwgzc | Hgrnlyj | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qytdtbzpg | Kydlykw | $65B | |||
| argenx SE ADR
ARGX
| Fjqtgmyn | Zwc | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kpzxzfpn | Lltctwk | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Kxccykqvnh | Bplnv | $25B | |||
| BioNTech SE ADR
BNTX
| Qwwvptb | Msz | $22B | |||
| Incyte Corp
INCY
| Vhrfbzbm | Zsqlj | $21B | |||
| Moderna Inc
MRNA
| Ndlzfgvgj | Nwbww | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Hzghfwlpv | Yjxd | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Wzyppkyv | Mydz | $13B |
United States